NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT00634751,"CO07204-Phase I/II of Oxaliplatin, Capecitabine & Sorafenib for Advanced Pancreatic & Biliary Carcinoma",https://clinicaltrials.gov/study/NCT00634751,,COMPLETED,"This study involves the use of oxaliplatin, capecitabine, and sorafenib which are all drugs approved by the Food and Drug Administration (FDA) for use in the treatment of different cancers. Their use in this exact combination is considered experimental for the treatment of pancreas and biliary tract; however the combination has been tested in a preliminary trial. We are also testing a survey designed. The purpose of this research study is to investigate the chemotherapy drug sorafenib in combination with oxaliplatin and capecitabine chemotherapies for the treatment of pancreas and biliary tract cancers.to help patients report their side effects from chemotherapy treatments.",YES,Pancreatic Neoplasms|Bile Duct Neoplasms,DRUG: Oxaliplatin|DRUG: Capecitabine|DRUG: Sorafenib,"Overall Response Rate, Response rate of participant to treatment, Up to 18 months","Progression-free Survival (PFS), Time to progression, defined as number of days from day of first study drug administration to the day the patient experiences an event of disease progression or death; summarized using point estimates of the median time to progression and associated 95% confidence intervals for each stratum separately., Up to 18 months|Overall Survival, Overall survival, defined as number of days from the day of first study drug administration to the day the patient dies, summarized using point estimates of the median time to progression, and associated 95% confidence intervals, Up to 18 months",,"University of Wisconsin, Madison",Bayer|Sanofi,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,48,OTHER,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2007-0248|CO07204|H-2007-0248|NCI-2011-00475|A534260|SMPH\MEDICINE\HEM-ONC,2008-02,2010-07,2010-07,2008-03-13,2017-06-12,2019-11-26,"University of Wisconsin, Madison, Wisconsin, 53792, United States",
